Szemraj, Janusz <br/><br/>
A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.  [electronic resource] 

 -  Thrombosis and haemostasis  Jun 2007 
 - 1037-45 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-6245 
<br/><br/><label>Standard No.: </label>10.1160/th06-10-0562  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bleeding Time<br/>Blood Coagulation--drug effects<br/>Carotid Artery Thrombosis--blood<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Electric Stimulation<br/>Fibrin--metabolism<br/>Fibrinolytic Agents--adverse effects<br/>Hemorrhage--chemically induced<br/>Hirudins--adverse effects<br/>Ligation<br/>Male<br/>Metalloendopeptidases--adverse effects<br/>Partial Thromboplastin Time<br/>Rats<br/>Rats, Wistar<br/>Recombinant Fusion Proteins--adverse effects<br/>Thrombin Time<br/>Time Factors<br/>Tissue Plasminogen Activator--pharmacology<br/>Vascular Patency--drug effects<br/>Venae Cavae--surgery<br/>Venous Thrombosis--blood